Coya Therapeutics sees success in early COYA-302 FTD trial, aims for Phase 2b in H2 2025 and ALS filing in Q2 2025. Read why COYA stock is a strong buy.

Oral dual-targeted ABCB4/BSEP positive functional modulator (PFM) improved cholestatic and cholangitis markers in orthogonal ...

Here, the floor belongs to basic science, as well as “first in human” and “proof of concept” phase 1 trials that shed light on brand-new treatment approaches. Below are a sampling of early ...

"Callio raises $187m for proof-of-concept for dual-payload ADC" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...

LILLE & PARIS, France--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing ... to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 ...

LTR Pharma Limited (ASX:LTP) has entered into a development agreement with US-based Strategic Drug Solutions, Inc ...

Introduction: The Convergence of AI and Life SciencesTraditionally, drug discovery is a time-consuming and costly process, ...

GOSSELIES, Belgium and NANTES, France, May 7, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of peo ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.

Proof of Concept, an accelerator program supporting women, trans and nonbinary filmmakers founded by Oscar winner Cate Blanchett, producer Coco Francini and noted researcher Dr. Stacy L.